Karthaus M, Carratalà J, Jürgens H, Ganser A
Department of Haematology and Oncology, Hannover Medical School, Hannover, Germany.
Chemotherapy. 1998 Nov-Dec;44(6):427-35. doi: 10.1159/000007155.
Febrile neutropenia is associated with a significant risk of complications and mortality. Patients with neutropenia secondary to cytostatic chemotherapy who develop fever are normally admitted to hospital and treated promptly with broad-spectrum antibiotics. Over the last 10 years, chemotherapy for solid tumours has been shifting out of the hospital setting into the ambit of community-based oncologists, and out-patient treatment with complex multidrug protocols is becoming increasingly common. In North America high-dose protocols combined with peripheral blood stem cell transfusion are already being administered on an out-patient basis. With the increase in the numbers of out-patients undergoing multidrug chemotherapy, there has been a corresponding rise in the severity and duration of neutropenia and in the incidence of associated infections. Patients with neutropenia of short duration (<7 days) and fever are at a relatively low risk for complications, and in these circumstances, out-patient antibiotic treatment is an alternative to costly hospitalisation. Drugs, whose antimicrobial coverage and pharmacokinetics make them particularly suitable for out-patient treatment of febrile neutropenia, include intravenous and oral quinolones and, for once-daily dosing, intravenous glycopeptides, ceftriaxone and intravenous aminoglycosides. Response rates of 60-95% have been achieved with such regimens in clinical trials, with hospital admission avoided in 75-95% of the cases. There is no doubt that out-patient treatment improves the quality of life of cancer patients. In Europe, however, there is a need for randomised clinical trials to support the establishment of out-patient-based treatment of febrile neutropenia. Out-patient antibiotic treatment of febrile neutropenia is still not standard practice, and community-based providers of such treatment must be adequately equipped and experienced in the management of this condition.
发热性中性粒细胞减少症与并发症及死亡的重大风险相关。因细胞毒性化疗继发中性粒细胞减少症且发热的患者通常会住院,并立即接受广谱抗生素治疗。在过去十年中,实体瘤化疗已从医院环境转向社区肿瘤学家的范围,采用复杂多药方案的门诊治疗越来越普遍。在北美,高剂量方案联合外周血干细胞输注已在门诊进行。随着接受多药化疗的门诊患者数量增加,中性粒细胞减少症的严重程度和持续时间以及相关感染的发生率相应上升。中性粒细胞减少持续时间短(<7天)且发热的患者并发症风险相对较低,在这种情况下,门诊抗生素治疗是昂贵住院治疗的一种替代选择。其抗菌覆盖范围和药代动力学使其特别适合门诊治疗发热性中性粒细胞减少症的药物包括静脉内和口服喹诺酮类药物,以及用于每日一次给药的静脉内糖肽类、头孢曲松和静脉内氨基糖苷类药物。在临床试验中,此类方案的有效率达到60 - 95%,75 - 95%的病例避免了住院。毫无疑问,门诊治疗改善了癌症患者的生活质量。然而,在欧洲,需要进行随机临床试验以支持建立基于门诊的发热性中性粒细胞减少症治疗方法。发热性中性粒细胞减少症的门诊抗生素治疗仍不是标准做法,提供此类治疗的社区医疗机构必须具备充分的设备并在管理这种病症方面有经验。